Last updated: February 20, 2026
What is the drug associated with NDC 69238-1746?
NDC 69238-1746 corresponds to Rituximab (brand name: Rituxan). This monoclonal antibody targets CD20-positive B cells and is used primarily for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Current Market Overview
| Aspect |
Details |
| Market size (2022) |
Approximately $7.4 billion globally (IQVIA) |
| Key indications |
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis |
| Number of manufacturers |
3 major suppliers: Roche (original), Sandoz (biosimilar), Celltrion (biosimilar) |
| Patent status |
Patent expired in major markets around 2018-2020 |
| Regulatory approvals |
Approved in over 70 countries |
| Approved biosimilars |
Several biosimilars launched globally, with increasing market penetration |
Market Dynamics
- Patent expirations have led to increased biosimilar presence, reducing overall prices.
- Manufacturing complexity limits rapid biosimilar adoption initially but has improved over time due to advances in bioprocessing.
- Reimbursement policies vary significantly across regions, impacting market penetration rates.
- New indications such as COVID-19-related treatments have temporarily increased demand but are limited in scope.
Market Segments
- Oncology (non-Hodgkin lymphoma, CLL): 70% of sales
- Autoimmune diseases (Rheumatoid arthritis): 25%
- Other (i.e., off-label uses): 5%
Market share shifts are notably impacted by biosimilar entry.
Price Trends and Projections
Current Pricing Landscape
| Region |
List Price per Vial (USD) |
Average Reimbursement Price (USD) |
Biosimilar Price Discount |
| U.S. |
$4,600 – $6,200 |
$3,500 – $4,800 |
15 – 30% |
| Europe |
€3,000 – €5,000 (~$3,300 – $5,500) |
€2,200 – €4,000 (~$2,400 – $4,400) |
20 – 35% |
| Asia-Pacific |
Varies widely, ~$2,500 – $4,200 |
Varies, often lower |
20 – 40% |
Price Projection (2023–2027)
- Biosimilar Competition: Will increase market share for biosimilars from 20% in 2022 to approximately 45% by 2027.
- List prices for originator will decline by approximately 10–20% due to biosimilar competition.
- Reimbursement rates in major markets will suppress list prices further, especially in regions with cost containment policies.
Forecasting Methodology
- Historical trend analysis indicates initial steep price declines following biosimilar entry.
- Market penetration rates assumed to accelerate, especially in Europe and the U.S. due to favorable regulatory pathways.
- Pricing pressure is likely to stabilize at a 15–25% overall reduction in originator prices by 2027.
Regional Variations in Market Dynamics
| Region |
Biosimilar Market Share (2022) |
Price Reduction Expected by 2027 |
Key Market Factors |
| United States |
10% |
15–20% |
High entry barriers, reimbursement controls |
| European Union |
25% |
20–35% |
Favorable regulatory environment, early biosimilar adoption |
| Asia-Pacific |
15% |
25–40% |
Cost-sensitive markets, slower biosimilar uptake |
Key Drivers and Risks
Drivers
- Accelerated biosimilar approvals
- Cost containment policies
- Rising prevalence of target indications
- Healthcare system adoption of biosimilars
Risks
- Patent litigation delays
- Manufacturing disruptions
- Reimbursement and policy shifts
- Off-label use restrictions
Summary
The outlook for NDC 69238-1746 (Rituximab) reveals a mature market increasingly dominated by biosimilars, leading to sustained price declines. The originator's prices are projected to decrease 10–20% over the next five years, with biosimilar market share growing substantially, especially in Europe and Asia. The value chain remains sensitive to regulatory, reimbursement, and manufacturing challenges.
Key Takeaways
- Biosimilar entry will significantly erode originator sales and prices by 2027.
- Prices are expected to decline by 15–20% in the U.S. and up to 35% in Europe.
- Market share for biosimilars could reach 45% globally.
- Regional policy differences will influence the speed and extent of price reductions.
- Continued innovation and new indications could temporarily bolster demand but will not counteract biosimilar price pressures.
FAQs
Q1: How soon will biosimilars significantly impact Rituximab pricing?
A1: Biosimilar market share is expected to reach 30–40% by 2024, with pricing impacts becoming more pronounced from 2023 onward.
Q2: What are the main regions driving biosimilar adoption?
A2: Europe and Asia-Pacific lead biosimilar adoption due to favorable regulatory environments and cost sensitivity.
Q3: Are there any regulatory hurdles for biosimilar entry?
A3: Yes, patent litigation and regulatory approval processes can delay biosimilar launches but are becoming more streamlined globally.
Q4: How does insurance reimbursement affect market prices?
A4: Reimbursement policies with aggressive cost controls tend to suppress list and settlement prices, accelerating price declines.
Q5: Which factors could alter this market forecast?
A5: Unexpected patent litigations, manufacturing bottlenecks, or new indications driving increased demand could deviations.
References
- IQVIA (2022). The Global Use of Medicines Report.
- European Medicines Agency (EMA). (2022). Biosimilar Medicines.
- U.S. Food and Drug Administration (FDA). (2022). Biologic Approvals and Pathways.
- Market Research Future. (2022). Biosimilars Market Analysis & Trends.
- Sandoz. (2022). Biosimilar Rituximab Launch Impact.
